Desloratadine
| Evidence Level: L5 | Predicted Indications: 53 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Desloratadine |
| DrugBank ID | DB00967 |
| Brand Names (EU) | Aerinaze, Dasselta, Desloratadine ratiopharm |
| Evidence Level | L5 |
| Predicted Indications | 53 |
| Top Prediction Score | 99.99% |
Approved Indication (EMA)
Dasselta is indicated for the relief of symptoms associated with: allergic rhinitis; urticaria.
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | allergic urticaria | 99.99% | DL |
| 2 | papillary conjunctivitis | 99.97% | DL |
| 3 | cold urticaria | 99.94% | DL |
| 4 | pharyngitis | 99.87% | DL |
| 5 | nasal cavity disease | 99.87% | DL |
| 6 | acute laryngopharyngitis | 99.85% | DL |
| 7 | atopic conjunctivitis | 99.84% | DL |
| 8 | vernal conjunctivitis | 99.78% | DL |
| 9 | recalcitrant atopic dermatitis | 99.75% | DL |
| 10 | nasopharyngitis | 99.66% | DL |
| 11 | IgE responsiveness, atopic | 99.64% | DL |
| 12 | rosacea conjunctivitis | 99.40% | DL |
| 13 | common cold | 99.02% | DL |
| 14 | headache disorder | 98.44% | DL |
| 15 | trigeminal autonomic cephalalgia | 98.33% | DL |
| 16 | punctate epithelial keratoconjunctivitis | 97.68% | DL |
| 17 | Angelucci syndrome | 97.64% | DL |
| 18 | chronic follicular conjunctivitis | 97.62% | DL |
| 19 | parasitic conjunctivitis | 97.62% | DL |
| 20 | serous conjunctivitis except viral | 97.62% | DL |
Showing top 20 of 53 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.